RRML - Assessment of beta cell function in subjects with newly diagnosed type 2 diabetes
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- May 2021 -
 
Prognostic value of serum lact... 15
Romanian Review of Laboratory ... 8
Pseudohyponatremia and falsely... 8
Vaginal candidiasis in Konya a... 7
The possibility of clinical us... 7
Evaluation of Plasma AA/DHA+EP... 6
Prevalence of ∆F508 cystic f... 6
Predictors associated with inc... 6
Reliability of Friedewald form... 5
Frequency, Distribution and Ge... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 21(2)/2013 DOI:10.2478/rrlm-2013-0011
XML
TXT

Assessment of beta cell function in subjects with newly diagnosed type 2 diabetes

Simona Cernea, Adina Huţanu, Ligia Coroş, Minodora Dobreanu


Abstract:

Objectives: The primary aim of this study was to assess residual beta cell function at diagnosis of type 2 diabetes and identify accessible laboratory markers that best estimate it. The secondary objective was to evaluate the change in beta cell function 6 months after starting different therapeutical regimens. Materials and methods: Forty seven subjects were included in the study and each performed a 75-g oral glucose tolerance test (OGTT) at baseline and after 6 months. Metabolic and immunologic parameters were determined from fasting samples. According to the degree of metabolic decompensation, specific therapy was started: metformin, metformin plus gliclazide or insulin therapy (with/out metformin). Early and total beta cell function was evaluated by the disposition index (DI) calculated for 30 minutes and 120 minutes, respectively. Results: At diagnosis, fasting blood glucose (BG) and HbA1c varied largely (129-521 mg/dl and 5.5-14%, respectively). The DI30 and DI120 decreased with more severe glycemic decompensation. For both DI30 and DI120 significant negative correlations were found for glycemic markers (HbA1c, 2-hour BG and maximal BG amplitude) and positive correlation for 2-hour C peptide (p<0.0001 for all). HbA1c value of 7% discriminated an important decrease of DI30 and DI120. Insulin and combined therapy significantly improved DI120 at 6 months (p: 0.0062 and 0.01, respectively), while DI30 was improved only with insulin therapy (p: 0.0326). Conclusions: Beta cell function at onset correlated with HbA1c, 2-hour BG and C peptide during OGTT. Thus OGTT and HbA1c are pivotal for evaluation of beta cell function. Insulin therapy improved early and total insulin secretion at 6 months.

Keywords: type 2 diabetes,beta cell function,biological markers,insulin therapy

 
  PDF Download full text PDF
(902 KB)
     
 
How to cite
Cernea S, Huţanu A, Coroş L, Dobreanu M. Assessment of beta cell function in subjects with newly diagnosed type 2 diabetes. Rev Romana Med Lab. 2013;21(2):145-60. DOI:10.2478/rrlm-2013-0011